Treatment of Chronic Lymphocytic Leukemia with Kinase inhibitors blocking B-cell receptor signaling and the BCL2 (B-cell lymphoma 2) antagonist venetoclax. B세포 수용체 신호전달을 차단하는 키나제 억제제와 BCL2(B세포 림프종 2) 길항제 베네토클락스를 이용한 만성 림프구성 백혈병 치료
J.A. Burger
Kinase inhibitors blocking B-cell receptor signaling and the BCL2 (B-cell lymphoma 2) antagonist venetoclax have been introduced and are fundamentally changing the chronic lymphocytic leukemia (CLL) treatment landscape.